GSK Takes Rare Diseases Option from Prosensa
This article was originally published in Start Up
Executive Summary
GlaxoSmithKline's tie-up with Dutch biotech Prosensa around four RNA-modulating therapeutics for Duchenne Muscular Dystrophy, a rare genetic disorder, provides recent evidence that even the largest Big Pharma are embracing the most niche of specialist disease indications.
You may also be interested in...
Rare Form: GSK, NEA Back Orphan Disease Venture Fund
A new fund offering access to European translational research focused on rare diseases has high-profile backers and reunites key players in the successful Prosensa IPO.
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.
Shire Finds Another Orphan Opportunity, Licenses Acceleron's DMD Drug
The deal gives the Irish pharma rights outside the U.S. and Canada to an entire family of proteins that address muscle disorders.